NASDAQ:SILO Silo Pharma (SILO) Stock Price, News & Analysis $0.63 -0.01 (-1.72%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Silo Pharma Stock (NASDAQ:SILO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Silo Pharma alerts:Sign Up Key Stats Today's Range$0.62▼$0.6650-Day Range$0.43▼$1.1652-Week Range$0.41▼$4.50Volume215,571 shsAverage Volume2.37 million shsMarket Capitalization$2.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSilo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.Read More… Silo Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreSILO MarketRank™: Silo Pharma scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Silo Pharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Silo Pharma is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silo Pharma is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilo Pharma has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Silo Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.13% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently increased by 216.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilo Pharma does not currently pay a dividend.Dividend GrowthSilo Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.13% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently increased by 216.03%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.27 News SentimentSilo Pharma has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Silo Pharma this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for SILO on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows4 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Silo Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,300.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.37% of the stock of Silo Pharma is held by insiders.Percentage Held by InstitutionsOnly 5.58% of the stock of Silo Pharma is held by institutions.Read more about Silo Pharma's insider trading history. Receive SILO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SILO Stock News HeadlinesSilo Pharma and Hoth Therapeutics plan joint venture for obesity treatmentJune 26, 2025 | investing.comSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market - MorningstarJune 26, 2025 | morningstar.comMThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being built now will dwarf everything that came before them. Thanks to AI's ravenous hunger for power … They are beginning to morph into sprawling behemoths. | Weiss Ratings (Ad)Silo Pharma and Hoth Therapeutics to Form Joint Venture for VA-Developed Obesity Treatment - NasdaqJune 26, 2025 | nasdaq.comSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketJune 25, 2025 | globenewswire.comHoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.June 25, 2025 | prnewswire.comSilo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | finanznachrichten.deSilo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | globenewswire.comSee More Headlines SILO Stock Analysis - Frequently Asked Questions How have SILO shares performed this year? Silo Pharma's stock was trading at $0.89 at the beginning of 2025. Since then, SILO shares have decreased by 29.2% and is now trading at $0.63. View the best growth stocks for 2025 here. How were Silo Pharma's earnings last quarter? Silo Pharma, Inc. (NASDAQ:SILO) announced its earnings results on Friday, May, 9th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.02 million for the quarter. Silo Pharma had a negative trailing twelve-month return on equity of 84.88% and a negative net margin of 6,420.83%. How do I buy shares of Silo Pharma? Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silo Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Sunshine Biopharma (SBFM), AbbVie (ABBV) and Biorestorative Therapies (BRTX). Company Calendar Last Earnings5/09/2025Today6/30/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryApparel Current SymbolNASDAQ:SILO CIK1514183 Websilopharma.com Phone(718) 400-9031FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.39 million Net Margins-6,420.83% Pretax Margin-6,419.44% Return on Equity-84.88% Return on Assets-61.81% Debt Debt-to-Equity RatioN/A Current Ratio4.73 Quick Ratio4.73 Sales & Book Value Annual Sales$70 thousand Price / Sales40.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book0.56Miscellaneous Outstanding Shares4,480,000Free Float4,288,000Market Cap$2.82 million OptionableNot Optionable Beta0.02 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:SILO) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMost Americans have no idea this plan exists...A Dollar Crash Is Coming - Here's When It Could Happen Already in 2025, the U.S. dollar has lost more value...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.